Senti Biosciences Reports $4.2 Million Net Loss and First Revenue Generation in Q1 2026

Senti Biosciences, Inc. reported a net loss of $4.2 million for the first quarter of 2026, a significant improvement compared to a net loss of $14.1 million during the same period in 2025. The company's collaboration revenue for the quarter was $16,000, marking its first revenue generation, attributed to an option exercise period extension fee from a related party. Total operating expenses decreased to $4.6 million from $16.4 million year-over-year, primarily due to reduced research and development costs, which fell from $9.3 million to $5.3 million, and a one-time gain of $6.9 million from a lease modification.

As of March 31, 2026, Senti's cash and cash equivalents stood at $8.9 million, down from $16.4 million at the end of 2025. The company reported an accumulated deficit of $362.8 million, reflecting ongoing investments in its gene circuit platform technologies and clinical development efforts. The decrease in cash was attributed to net cash used in operating activities of $7.5 million, which was lower than the $14.1 million used in the same quarter of the previous year, indicating improved cash management.

Strategically, Senti has undergone significant organizational changes, including a holding company reorganization completed on April 24, 2026, which positioned Senti Biosciences Holdings, Inc. as the successor issuer to Former Senti. This reorganization did not alter the company's operations or management structure. Additionally, Senti entered into a securities purchase agreement on April 27, 2026, to issue up to $40 million in senior secured convertible notes, with the first tranche expected to provide $10 million in gross proceeds. This funding is crucial for maintaining operations and advancing clinical trials for its lead product candidate, SENTI-202.

Operationally, Senti has made strides in its lease agreements, notably restructuring its Alameda Lease and related sublease arrangements with GeneFab, which has been a critical partner in its clinical manufacturing efforts. The amendments to these leases have reduced future rent obligations and addressed previous defaults, thereby stabilizing the company's operational costs. As of March 31, 2026, Senti's employee headcount remained consistent, supporting its ongoing research and development initiatives.

Looking ahead, Senti anticipates continued operating losses as it progresses with its clinical development programs. The company expects to incur substantial expenses related to advancing its gene circuit platform technologies and initiating additional preclinical studies. Management has indicated that while they are actively pursuing additional funding, there is substantial doubt about the company's ability to continue as a going concern without securing further capital. The successful execution of its funding strategy will be critical for sustaining operations and achieving its long-term objectives in the biotechnology sector.